Jupiter Topco’s ImmunityBio IBRX Stock Holding History

Jupiter Topco’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.38M	Buy	+157,439	New	+$1.19M	﹤0.01%	1647

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Jupiter Topco's IBRX Position: Q2 2026 in Review

Jupiter Topco opened a new position in ImmunityBio (IBRX) in Q2 2026: 157,439 shares worth $1.38M. The stake represents ﹤0.01% of the portfolio and ranks #1647 among its holdings.

377 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Jupiter Topco held 157,439 shares of ImmunityBio worth $1.38M as of Q2 2026.
ImmunityBio was a new Jupiter Topco position in Q2 2026.
ImmunityBio made up ﹤0.01% of Jupiter Topco's portfolio in Q2 2026, its #1647 holding.
377 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Jupiter Topco's 13F filing for Q2 2026, filed 14 Aug 2026.